Titre
Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Fuchs, A.
Auteure/Auteur
Zimmermann, L.
Auteure/Auteur
Bickle Graz, M.
Auteure/Auteur
Cherpillod, J.
Auteure/Auteur
Tolsa, J.F.
Auteure/Auteur
Buclin, T.
Auteure/Auteur
Giannoni, E.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1932-6203
Statut éditorial
Publié
Date de publication
2016
Volume
11
Numéro
7
Première page
e0158806
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
To evaluate the impact of gentamicin exposure on sensorineural hearing loss (SNHL) in very low birth weight (VLBW) infants.
Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gestational age < 32 weeks and/or with a birthweight < 1500 g, who presented with SNHL during the first 5 years of life. For each case, we selected two controls matched for gender, gestational age, birthweight, and year of birth.
We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in our population of VLBW infants. The proportion of infants treated with gentamicin was 76% in the study group and 70% in controls (p = 0.78). The total cumulated dose of gentamicin administered did not differ between the study group (median 10.2 mg/kg, Q1-Q3 1.6-13.2) and the control group (median 7.9 mg/kg, Q1-Q3 0-12.8, p = 0.47). The median duration of gentamicin treatment was 3 days both in the study group and the control group (p = 0.58). Maximum predicted trough serum levels of gentamicin, cumulative area under the curve and gentamicin clearance were not different between cases and controls.
The impact of gentamicin on SNHL can be minimized with treatments of short duration, monitoring of blood levels and dose adjustment.
Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gestational age < 32 weeks and/or with a birthweight < 1500 g, who presented with SNHL during the first 5 years of life. For each case, we selected two controls matched for gender, gestational age, birthweight, and year of birth.
We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in our population of VLBW infants. The proportion of infants treated with gentamicin was 76% in the study group and 70% in controls (p = 0.78). The total cumulated dose of gentamicin administered did not differ between the study group (median 10.2 mg/kg, Q1-Q3 1.6-13.2) and the control group (median 7.9 mg/kg, Q1-Q3 0-12.8, p = 0.47). The median duration of gentamicin treatment was 3 days both in the study group and the control group (p = 0.58). Maximum predicted trough serum levels of gentamicin, cumulative area under the curve and gentamicin clearance were not different between cases and controls.
The impact of gentamicin on SNHL can be minimized with treatments of short duration, monitoring of blood levels and dose adjustment.
Sujets
PID Serval
serval:BIB_8AEAB3EBFFC4
PMID
Open Access
Oui
Date de création
2016-07-14T14:45:59.934Z
Date de création dans IRIS
2025-05-21T02:10:09Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
BIB_8AEAB3EBFFC4.P001.pdf
Version du manuscrit
published
Taille
202.65 KB
Format
Adobe PDF
PID Serval
serval:BIB_8AEAB3EBFFC4.P001
URN
urn:nbn:ch:serval-BIB_8AEAB3EBFFC41
Somme de contrôle
(MD5):a27cade444ace0d7ed38319e1cee61db